In a filing, Applied Therapeutics Inc revealed its Chief Medical Officer Perfetti Riccardo unloaded Company’s shares for reported $4561.0 on Mar 04 ’25. In the deal valued at $0.44 per share,10,366 shares were sold. As a result of this transaction, Perfetti Riccardo now holds 890,409 shares worth roughly $0.35 million.
Then, Funtleyder Leslie D. sold 14,502 shares, generating $6,381 in total proceeds. Upon selling the shares at $0.44, the insider now owns 390,459 shares.
Before that, Chinoporos Constantine sold 447 shares. Applied Therapeutics Inc shares valued at $197 were divested by the insider at a price of $0.44 per share. As a result of the transaction, Chinoporos Constantine now holds 271,436 shares, worth roughly $0.11 million.
William Blair downgraded its Applied Therapeutics Inc [APLT] rating to a Mkt perform from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including UBS’s analysts, who decreased its forecast for the stock in early December from “a Buy” to “a Neutral”. RBC Capital Mkts also remained covering APLT and has decreased its forecast on November 29, 2024 with a “Sector perform” recommendation from previously “an Outperform” rating. William Blair started covering the stock on July 31, 2024. It rated APLT as “an Outperform”.
Price Performance Review of APLT
On Tuesday, Applied Therapeutics Inc [NASDAQ:APLT] saw its stock fall -2.25% to $0.39. Over the last five days, the stock has gained 8.46%. Applied Therapeutics Inc shares have fallen nearly -54.91% since the year began. Nevertheless, the stocks have fallen -91.42% over the past one year.
How much short interest is there in Applied Therapeutics Inc?
A steep rise in short interest was recorded in Applied Therapeutics Inc stocks on 2025-05-15, growing by 3.69 million shares to a total of 19.79 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 16.1 million shares. There was a rise of 18.66%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 26, 2024 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $12 price target.
